NCT00077922 2018-01-23
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
Clinical Trials
1 trialsHematologic Diseases × B3(Fv)-PE38KDEL recombinant immunotoxin × Other hematologic neoplasm × Clear all